Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2221 to 2235 of 8796 results

  1. Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]

    Awaiting development Reference number: GID-TA11088 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]

    Awaiting development Reference number: GID-TA10198 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]

    Awaiting development Reference number: GID-TA11076 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Edaravone for treating amyotrophic lateral sclerosis [TSID11869]

    Awaiting development Reference number: GID-TA11362 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037]

    Awaiting development Reference number: GID-TA11059 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor [TSID8376]

    Awaiting development Reference number: GID-TA11608 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]

    Awaiting development Reference number: GID-TA11558 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset [TSID10190]

    Awaiting development Reference number: GID-TA11283 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID11949]

    Awaiting development Reference number: GID-TA11465 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Leriglitazone for treating X-linked andrenoleukodystrophy [TSID9996]

    Awaiting development Reference number: GID-TA11393 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping [TSID10593]

    Awaiting development Reference number: GID-TA10957 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912]

    Awaiting development Reference number: GID-TA10797 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [TSID10690]

    Awaiting development Reference number: GID-TA11073 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436]

    Awaiting development Reference number: GID-TA11532 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy [TSID10764]

    Awaiting development Reference number: GID-TA11049 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development